Morgan Stanley raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $86 from $71 and keeps an Overweight rating on the shares following positive Phase 3 CORE/CORE2 results for olezarsen in severe hypertriglyceridemia. Recent positive feedback from key opinion leader physicians and favorable comments by management on pricing leverage at the firm’s Healthcare Conference leads the firm to raise its U.S. olezarsen price expectation in SHTG to the high end of the range, or $20,000, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $83 from $81 at BofA
- Ionis Pharmaceuticals price target raised to $92 from $90 at Guggenheim
- Buy Rating for Ionis Pharmaceuticals: Promising Phase 3 Results for Zilganersen in Alexander Disease
- Buy Rating Affirmed for Ionis Pharmaceuticals Amid Promising Phase III Results for Zilganersen in Treating Alexander Disease
- Morning Movers: Metsera surges, Pfizer gains after acquisition pact